Ifood

Movile Receives BRL $1 Billion Investment from Prosus

Retrieved on: 
Monday, August 2, 2021
Online food ordering, Movile, Video on demand services, Articles, Finance, Prosus, Money, Financial technology

SAO PAULO, August 2, 2021 PRNewswire-PRWeb/ -- Movile , one of Latin America's leading and longest standing investors and growth accelerators for technology companies, has received a new investment from Prosus totaling BRL $1 billion (USD $200 million), the largest primary investment in a single round since Movile's founding in 1998.

Key Points: 
  • SAO PAULO, August 2, 2021 PRNewswire-PRWeb/ -- Movile , one of Latin America's leading and longest standing investors and growth accelerators for technology companies, has received a new investment from Prosus totaling BRL $1 billion (USD $200 million), the largest primary investment in a single round since Movile's founding in 1998.
  • More recently, Movile invested another BRL$ 170 million in Zoop, one of Movile's fintech companies, as part of the new funding from Prosus.
  • Looking ahead, Hruby reveals that Movile will continue to search for companies that complement and add value to the existing Movile ecosystem.
  • Headquartered in So Paulo, Brazil, Movile is one of Latin America's largest investment groups and growth accelerators for technology companies.

How iFood Hit Over 150 Million REAIS In iFood Card Sales In 2020:

Retrieved on: 
Thursday, April 15, 2021
Mobile, Wireless, Technology, Other Retail, Security, Software, Food, Beverage, Internet, Data management, Retail, Online Retail, Online food ordering, Movile, Video on demand services, Just Eat, Omnichannel, Ifood, Articles, Websites, Service industries, Givex, iFood

As part of this evolution, in December 2019, iFood migrated its iFood Card program to the Givex platform, with the aim of making the iFood Card a 100% omnichannel product and integrated into all major sales channels in the country.\n\xe2\x80\x9cWe always seek partners who contribute to the innovation and pioneering of our operation.

Key Points: 
  • As part of this evolution, in December 2019, iFood migrated its iFood Card program to the Givex platform, with the aim of making the iFood Card a 100% omnichannel product and integrated into all major sales channels in the country.\n\xe2\x80\x9cWe always seek partners who contribute to the innovation and pioneering of our operation.
  • By June 2021, companies will distribute the iFood Card in 350,000 establishments via the sale of PINs and 13,000 points of sale with physical card.\nAll these initiatives that launched in 2020 with Givex technology have allowed iFood to reach the mark of 150 million reais sold in iFood Cards in one year.
  • Technology was indeed the main ally in this context, which allowed iFood and Givex to innovate, diversify, and scale the solution safely.
  • iFood counts major investors such as Movile - a global leader in mobile marketplaces - and Just Eat - one of the world\'s largest online ordering companies.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210415005058/en/\n'

Retrotope Granted Rare Pediatric Disease Designation from FDA for Lead Development Candidate, RT001, in Two Life-Threatening Neurodegenerative Indications

Retrieved on: 
Thursday, February 25, 2021
Rare diseases, Branches of biology, Clinical medicine, Health, Retrotope, Priority review, Di-deuterated linoleic acid ethyl ester, Food and Drug Administration, Infantile neuroaxonal dystrophy, Friedreich's ataxia, Fast track, Ifood

The first rare pediatric disease designation is for the treatment of infantile neuroaxonal dystrophy (INAD), with the second covering the treatment of Friedreichs ataxia (FA).

Key Points: 
  • The first rare pediatric disease designation is for the treatment of infantile neuroaxonal dystrophy (INAD), with the second covering the treatment of Friedreichs ataxia (FA).
  • To qualify for rare pediatric disease designation, these diseases must affect fewer than 200,000 people in the United States.
  • Retrotope is eligible to receive a priority review voucher should the company secure approval for RT001 in either one of these indications.
  • Recipients of Fast Track designation are eligible for greater access to the FDA during the clinical development process and may also qualify for priority review.

iFood launches free digital bank accounts for all 236,000+ restaurants on its platform

Retrieved on: 
Wednesday, November 4, 2020
Service industries, Money, Finance, Online food ordering, Movile, Video on demand services, Debit cards, Credit cards, Visa Inc., Bank, Euronet Worldwide, Ifood

SO PAULO, Nov. 4, 2020 /PRNewswire-PRWeb/ -- iFood , the leading foodtech in Latin America, announced today that it has launched the first "bank for restaurants" in Brazil via an exclusive iFood Digital Account for restaurants registered on the iFood online delivery platform.

Key Points: 
  • SO PAULO, Nov. 4, 2020 /PRNewswire-PRWeb/ -- iFood , the leading foodtech in Latin America, announced today that it has launched the first "bank for restaurants" in Brazil via an exclusive iFood Digital Account for restaurants registered on the iFood online delivery platform.
  • The iFood Digital Account was developed by MovilePay, one of Movile Group's fintechs, and is integrated with a prepaid Visa card announced in August.
  • The new iFood Digital Account brings together several services in a single portfolio.
  • With the new iFood Digital Account, restaurants will have access to less transaction fees and much lower credit interest rates.

US FDA Grants Orphan Drug Designation for Retrotope’s RT001 in the Treatment of Progressive SupraNuclear Palsy (PSP)

Retrieved on: 
Tuesday, February 18, 2020
Health, Pharmaceuticals policy, Articles, Food and Drug Administration, Life sciences, Biochemistry, Di-deuterated linoleic acid ethyl ester, Retrotope, Orphan drug, Orphan Drug Act, Breakthrough therapy, Ifood

LOS ALTOS, Calif., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Retrotope announced today that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development granted orphan drug designation for its chemically-modified polyunsaturated fatty acid drug (RT001) for the treatment of Progressive SupraNuclear Palsy (PSP).

Key Points: 
  • LOS ALTOS, Calif., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Retrotope announced today that the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development granted orphan drug designation for its chemically-modified polyunsaturated fatty acid drug (RT001) for the treatment of Progressive SupraNuclear Palsy (PSP).
  • This orphan designation encourages clinical trials and rapid review of data from trials to treat this intractable disease.
  • The US FDA Orphan Drug Act (ODA) provides orphan designation for drugs and biological products to treat a rare disease or condition upon request of a sponsor.
  • Orphan designation qualifies the sponsor of the drug for various development incentives of the ODA, including tax credits for qualified clinical testing.

iFood reaches 14.1 Mi monthly orders in Brazil and will hire 1,000 people in 2019

Retrieved on: 
Tuesday, February 5, 2019
Online food ordering, Movile, Ifood

Throughout 2019, iFood will hire more than 1,000 employees.

Key Points: 
  • Throughout 2019, iFood will hire more than 1,000 employees.
  • Fabricio Bloisi, Movile's CEO, explains: "We strongly believe in the Brazilian market potential and iFood is an example of everything we can achieve.
  • Movile aims to positively impact the lives of 1 billion people, and iFood is an essential part of this challenge.
  • As a result, the time it takes to fulfill the route between them and the restaurant decreases significantly.